SLC5A2 and type 2 diabetes mellitus: The results from the above five CVOTs were meta-analyzed by Marilly et al. It has been confirmed that the use of SGLT2 inhibitors in patients with T2DM reduced the risk of all-cause mortality and MACE by 14% (0.86; 95% CI, 0.78–0.95) and 9% (0.91; 95% CI, 0.86–0.96), respectively.